Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination

• 1. 间变性淋巴瘤激酶(ALK)核酸和ALK融合转录物的基于血浆的检测及其在癌症诊断和治疗中的用途 [P] . 中国专利： CN109563547A . 2019-04-02
• 2. 用于诊断和治疗抗间变性淋巴瘤激酶(ALK)激酶抑制剂的癌症的方法和组合物 [P] . 中国专利： CN103201286B . 2017.05.03
• 3. Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination [P] . 美国专利： US8980287B2 . 2015-03-17

  机译： 间变性淋巴瘤激酶（ALK）作为癌抗原用于淋巴瘤疫苗接种

• 4. ANAPLASTIC LYMPHOMA KINASE (ALK) AS ONCOANTIGEN FOR LYMPHOMA VACCINATION [P] . 美国专利： US2015232820A1 . 2015-08-20

  机译： 无性淋巴激酶（ALK）作为致癌原用于淋巴疫苗接种

• 5. Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination [P] . 欧洲知识产权局专利： EP2042191B1 . 2013-01-02

  机译： 间变性淋巴瘤激酶（ALK）作为癌抗原用于淋巴瘤疫苗接种

• 1. Relationship between molecular changes in epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in lung adenocarcinoma [J] . Rina Na, Wei Luan, Yinzai He, 中德临床肿瘤学杂志（英文版） . 2021,第004期
• 2. Relationship between molecular changes in epidermal growth factor receptor(EGFR)and anaplastic lymphoma kinase(ALK)mutations in lung adenocarcinoma [J] . Rina Na, Wei Luan, Yinzai He, 肿瘤学与转化医学（英文） . 2021,第004期
• 3. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. [J] . Ait Tahar K, Damm Welk C, Burkhardt B, Blood: The Journal of the American Society of Hematology . 2010,第16期
• 4. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. [J] . Chiarle R, Martinengo C, Mastini C, Nature medicine . 2008,第6期
• 5. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene [J] . Jo-Anne van der Krogt, Marlies Vanden Bempt, Julio Finalet Ferreiro, Haematologica . 2017,第9期
• 6. Functional characterization of ubiquitination profile changes induced by oncogenic protein NPM-ALK in ALK~(+) anaplastic large cell lymphoma cells [C] . Fang Wu, Peng Wang, Raymond Lai, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010
• 7. Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. [D] . Pearson, Joel Dylan. 2013
• 8. Alectinib an anaplastic lymphoma kinase (ALK) inhibitor as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin [O] . Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, 2019
• 9. Studies of Phosphoproteomic Changes Induced by Nucleophosmin-Anaplastic Lymphoma Kinase (ALK) Highlight Deregulation of Tumor Necrosis Factor (TNF)/Fas/TNF-related Apoptosis-induced Ligand Signaling Pathway in ALK-positive Anaplastic Large Cell Lymphoma* [O] . Wu, Fang, Wang, Peng, Zhang, Jingdong, 2010

• 1. Primary bone anaplastic lymphoma kinase positive anaplastic largecell lymphoma: A case report and review of the literature [J] . Wei Zheng ,Qiao-Qiao Yin ,Tian-Chen Hui . 世界临床病例杂志 . 2021,第014期
• 2. Acute leukemic phase of anaplastic lymphoma kinase-anaplastic large cell lymphoma: A case report and review of the literature [J] . Huai-Feng Zhang ,Yan Guo . 世界临床病例杂志 . 2020,第021期
• 3. Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma masquerading as Behcet''''s disease:A case report and review of literature [J] . Juan Luo ,Ying-Han Jiang ,Zi Lei . 世界临床病例杂志 . 2019,第020期
• 4. 咸阳市人群乙型肝炎疫苗接种率及乙型肝炎病毒表面抗原阳性率调查 [C] . 刘军礼 ,张亦军 . 2004年全国病毒性肝炎防治研讨会 . 2004
• 5. 间变性淋巴瘤激酶(ALK)抑制剂的设计、合成、生物活性评价和类药性化合物库的构建 [A] . 陈斌辉 . 2018